University of Manitoba, Winnipeg, Manitoba, R3E 0T5, Canada.
J Pharm Sci. 2013 Jan;102(1):227-36. doi: 10.1002/jps.23351. Epub 2012 Nov 6.
Polyethylene glycol (PEG) has been used widely in liposomal formulations as a strategy to inhibit opsonization by plasma proteins and to prolong liposome plasma circulation time. PEG can be incorporated onto the surface of liposomes either during the spontaneous self-assembling process or inserted after vesicle formation. The advantages of employing the PEG postinsertion method include improved drug encapsulation efficiency and the ability to incorporate PEG conjugates for enhanced cell binding and uptake. In this study, we propose to evaluate a cationic lipid nanoparticle formulation containing two PEGylation steps: pre- and post-siRNA insertion. Our results indicate that formulations consisting of the extra PEG post-insertion step significantly increased siRNA circulation in the plasma by two-folds in comparison with the formulations consisting of only the single PEGylation step. Moreover, this formulation was able to efficiently carry siRNA to the tumor site, increase siRNA stability and significantly downregulate luciferase mRNA expression by >50% when compared with the controls in an intraperitoneal and subcutaneous breast cancer tumor model. Overall, our cationic lipid nanoparticle formulation displayed enhanced plasma circulation, reduced liver accumulation, enhanced tumor targeting, and effective gene knockdown--demonstrating excellent utility for the delivery of siRNA.
聚乙二醇(PEG)已广泛应用于脂质体制剂中,作为一种抑制血浆蛋白调理作用并延长脂质体血浆循环时间的策略。PEG 可以在自发自组装过程中或在囊泡形成后整合到脂质体表面。采用 PEG 插入后方法的优点包括提高药物包封效率和能够结合 PEG 缀合物以增强细胞结合和摄取。在这项研究中,我们提出评估一种含有两个 PEGylation 步骤的阳离子脂质纳米颗粒制剂:siRNA 插入前和插入后。我们的结果表明,与仅包含单个 PEGylation 步骤的制剂相比,包含额外 PEG 插入后步骤的制剂可使 siRNA 在血浆中的循环增加两倍。此外,与对照组相比,这种制剂能够有效地将 siRNA 递送到肿瘤部位,提高 siRNA 的稳定性,并在腹膜内和皮下乳腺癌肿瘤模型中显著下调 >50%的荧光素酶 mRNA 表达。总的来说,我们的阳离子脂质纳米颗粒制剂显示出增强的血浆循环、减少肝脏积累、增强的肿瘤靶向和有效的基因敲低——证明了其在 siRNA 递送上的优异应用。
J Liposome Res. 2016-7-21
Adv Healthc Mater. 2014-6-20
Bioengineering (Basel). 2024-8-14
Front Bioeng Biotechnol. 2023-9-12